Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASY: Transition to Raptiva in Psoriasis
NCT00697593Phase 4Terminated
- Sponsor
- Merck KGaA
- Start
- Jan 2008
- Primary completion
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of efalizumab in plaque psoriasis, sponsored by Merck KGaA. Started Jan 2008; status: terminated.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00697593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00697593.